Recursion licence of Tempus de-identified records, total over the five-year term
$160.0 million
USD per five-year data licence (one contract), US
“Company will pay Tempus an initial license fee in an amount equal to $22.0 million...totals up to $160.0 million over the Term”
Recursion Pharmaceuticals Form 8-K, 9 November 2023 (Tempus master agreement), 2023-11
- Kind of source
- Regulatory filing
- Read on
- 2026-11-06
- Daily check
- Quote found at the source on 2026-11-06
- What to know
- The $160.0 million is the maximum, including a $22.0 million initial licence fee; Recursion can end the contract early only after the third anniversary.
Used in
Kept as evidence; no figure on the platform is computed from it yet.